Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals

Abstract

Previous articleNext article No AccessPersuasion or Information? Promotion and the Shares of Brand Name and Generic PharmaceuticalsMark A. Hurwitz and Richard E. CavesMark A. Hurwitz Search for more articles by this author and Richard E. Caves Search for more articles by this author PDFPDF PLUS Add to favoritesDownload CitationTrack CitationsPermissionsReprints Share onFacebookTwitterLinkedInRedditEmail SectionsMoreDetailsFiguresReferencesCited by The Journal of Law and Economics Volume 31, Number 2Oct., 1988 Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School Article DOIhttps://doi.org/10.1086/467158 Views: 57Total views on this site Citations: 137Citations are reported from Crossref Copyright 1988 The University of ChicagoPDF download Crossref reports the following articles citing this article:Tianqin Shi, Nicholas C. Petruzzi, Dilip Chhajed The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy, Manufacturing & Service Operations Management 24, no.22 (Mar 2022): 810–826.https://doi.org/10.1287/msom.2021.1009Farasat A. S. Bokhari, Franco Mariuzzo, Anna Rita Bennato Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions, Small Business Economics 57, no.11 (Apr 2020): 603–634.https://doi.org/10.1007/s11187-019-00307-wDemetrios Vakratsas, Aneel Keswani, David Stolin Advertising persuasion in dual markets, Managerial and Decision Economics 42, no.11 (Aug 2020): 239–245.https://doi.org/10.1002/mde.3229Harindranath R. M., Bharadhwaj Sivakumaran Pharmaceutical Promotion, (Jan 2021): 44–63.https://doi.org/10.4018/978-1-7998-3034-4.ch004Moritz Suppliet Umbrella branding in pharmaceutical markets, Journal of Health Economics 73 (Sep 2020): 102324.https://doi.org/10.1016/j.jhealeco.2020.102324Micael Castanheira, Carmine Ornaghi, Georges Siotis The unexpected consequences of generic entry, Journal of Health Economics 68 (Dec 2019): 102243.https://doi.org/10.1016/j.jhealeco.2019.102243Jörg Mahlich, B. Burcin Yurtoglu Returns on different types of investment in the global pharmaceutical industry, Managerial and Decision Economics 40, no.11 (Oct 2018): 16–36.https://doi.org/10.1002/mde.2977Ching-Wen Chang, Takayuki Yamanaka, Shingo Kano An enforced loop-out knowledge flow facilitates industry competition: Learning from the pharmaceutical and genetically modified seed industries, Technovation 79 (Jan 2019): 11–24.https://doi.org/10.1016/j.technovation.2018.06.004Yunyun Wan , The Japanese Economic Review 69, no.33 ( 2018): 340.https://doi.org/10.1111/jere.12189Melissa Newham, Jo Seldeslachts, Albert Banal Estaaol Common Ownership and Market Entry: Evidence from Pharmaceutical Industry, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3194394Atanu Saha Strategic Deterrence: An Application to Biologic Pharmaceuticals, SSRN Electronic Journal (Jan 2018).https://doi.org/10.2139/ssrn.3204424Alexander Summers, Carly Ruderman, Fok-Han Leung, Morgan Slater Examining patterns in medication documentation of trade and generic names in an academic family practice training centre, BMC Medical Education 17, no.11 (Sep 2017).https://doi.org/10.1186/s12909-017-1015-zSuraksha Gupta Returns from Strategies Adopted by MNEs to Improve Global Health and Wellbeing: Third Sustainable Development Goal, (Sep 2017): 151–172.https://doi.org/10.1108/S1876-066X20170000033007Bart J. Bronnenberg, Jean-Pierre Dubé The Formation of Consumer Brand Preferences, Annual Review of Economics 9, no.11 (Aug 2017): 353–382.https://doi.org/10.1146/annurev-economics-110316-020949Pankhuri Agarwal, Sharon Kaur Pharmaceutical Promotion and Its Influence on Prescription Behavior: Ethical Issues and Legal Framework in India, Asian Bioethics Review 9, no.1-21-2 (Jul 2017): 73–85.https://doi.org/10.1007/s41649-017-0011-2Suraksha Gupta Returns on social development initiatives of MNEs: issues and perspectives, Qualitative Market Research: An International Journal 20, no.22 (Apr 2017): 126–146.https://doi.org/10.1108/QMR-01-2017-0004Harindranath R.M., Jayanth Jacob Promotional support: a formative scale development, International Journal of Pharmaceutical and Healthcare Marketing 11, no.11 (Apr 2017): 97–110.https://doi.org/10.1108/IJPHM-04-2016-0023Wei Zhang, Huiying Sun, Daphne Guh, Aslam H. Anis The impact of price-cap regulations on market entry by generic pharmaceutical firms, Expert Review of Pharmacoeconomics & Outcomes Research 17, no.22 (Dec 2016): 231–238.https://doi.org/10.1080/14737167.2017.1271717Prokriti Mukherji, Ramkumar Janakiraman, Shantanu Dutta, Surendra Rajiv How Direct-to-Consumer Advertising for Prescription Drugs Affects Consumers' Welfare, Journal of Advertising Research 57, no.11 (Nov 2016): 94–108.https://doi.org/10.2501/JAR-2016-050Faris El-Dahiyat, Louise Elizabeth Curley Pharmaceutical Policy in Jordan, (Mar 2017): 237–260.https://doi.org/10.1007/978-3-319-51673-8_12Moritz Suppliet Umbrella Branding in Pharmaceutical Markets, SSRN Electronic Journal (Jan 2017).https://doi.org/10.2139/ssrn.3040045Lee Branstetter, Chirantan Chatterjee, Matthew J. Higgins Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry, The RAND Journal of Economics 47, no.44 (Nov 2016): 857–890.https://doi.org/10.1111/1756-2171.12157Jianfei Guo, Christina Kelton Competition between Brand-Name and Generic Drugs, (May 2016): 181–193.https://doi.org/10.1201/b19633-13Anna Rita Bennato, Farasat A. S. Bokhari, Franco Mariuzzo Growth and Returns to New Products and Pack Varieties: The Case of UK Pharmaceuticals, SSRN Electronic Journal (Jan 2016).https://doi.org/10.2139/ssrn.2758574Bart J. Bronnenberg The Formation of Consumer Brand Preferences, SSRN Electronic Journal (Jan 2016).https://doi.org/10.2139/ssrn.2841698Hye-Young Kwon, Hyungmin Kim, Brian Godman, Michael R Reich The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs, Expert Review of Pharmacoeconomics & Outcomes Research 15, no.66 (Sep 2015): 1007–1014.https://doi.org/10.1586/14737167.2015.1083425Silvia Appelt Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry, Review of Economics and Statistics 97, no.33 (Jul 2015): 654–666.https://doi.org/10.1162/REST_a_00488Alon Eizenberg, Alberto Salvo The Rise of Fringe Competitors in the Wake of an Emerging Middle Class: An Empirical Analysis, American Economic Journal: Applied Economics 7, no.33 (Jul 2015): 85–122.https://doi.org/10.1257/app.20130104Kathleen Iacocca, James Sawhill, Yao Zhao Why brand drugs priced higher than generic equivalents, International Journal of Pharmaceutical and Healthcare Marketing 9, no.11 (Apr 2015): 3–19.https://doi.org/10.1108/IJPHM-01-2014-0005Lobna Abdellatif, Mohamed Zaky Characteristics Of private markets and accessibility of small and medium enterprises to public procurement markets: Pharmaceuticals in egypt, Journal of Public Procurement 15, no.44 (Mar 2015): 476–513.https://doi.org/10.1108/JOPP-15-04-2015-B004Martin Spann, Marc Fischer, Gerard J. Tellis Skimming or Penetration? Strategic Dynamic Pricing for New Products, Marketing Science 34, no.22 (Mar 2015): 235–249.https://doi.org/10.1287/mksc.2014.0891Guy David, Sara Markowitz The Effect of Regulated Competition on Pharmaceutical Advertising and Promotion, Eastern Economic Journal 41, no.11 (Aug 2013): 24–39.https://doi.org/10.1057/eej.2013.30Joan Costa-Font, Alistair McGuire, Nebibe Varol Price regulation and relative delays in generic drug adoption, Journal of Health Economics 38 (Dec 2014): 1–9.https://doi.org/10.1016/j.jhealeco.2014.04.004Enar Ruiz-Conde, Jaap E. Wieringa, Peter S.H. Leeflang Competitive diffusion of new prescription drugs: The role of pharmaceutical marketing investment, Technological Forecasting and Social Change 88 (Oct 2014): 49–63.https://doi.org/10.1016/j.techfore.2014.06.006Andrew J. Epstein, Jonathan D. Ketcham Information technology and agency in physicians' prescribing decisions, The RAND Journal of Economics 45, no.22 (May 2014): 422–448.https://doi.org/10.1111/1756-2171.12057Yu Yu, Sachin Gupta Pioneering advantage in generic drug competition, International Journal of Pharmaceutical and Healthcare Marketing 8, no.22 (May 2014): 126–150.https://doi.org/10.1108/IJPHM-11-2013-0063Jaap E. Wieringa, Ernst C. Osinga, Enar Ruiz Conde, Peter S. H. Leeflang, Philip Stern Modeling the Effects of Promotional Efforts on Aggregate Pharmaceutical Demand: What We Know and Challenges for the Future, (Oct 2013): 591–628.https://doi.org/10.1007/978-1-4614-7801-0_20Ya-Ming Liu, Chee-Ruey Hsieh Profit-Seeking Behavior of Medical Providers and Generic Competition in the Pharmaceutical Market: Evidence from Taiwan, The B.E. Journal of Economic Analysis & Policy 14, no.11 (Nov 2013): 241–275.https://doi.org/10.1515/bejeap-2013-0066Martin Spann, Marc Fischer, Gerard J. Tellis Skimming or Penetration? Strategic Dynamic Pricing for New Products, SSRN Electronic Journal (Jan 2014).https://doi.org/10.2139/ssrn.2504719Alon Eizenberg, Alberto Salvo The Rise of Fringe Competitors in the Wake of an Emerging Middle Class: An Empirical Analysis, SSRN Electronic Journal (Jan 2014).https://doi.org/10.2139/ssrn.2580719Roger Feldman, Félix Lobo Competition in prescription drug markets: the roles of trademarks, advertising, and generic names, The European Journal of Health Economics 14, no.44 (Jul 2012): 667–675.https://doi.org/10.1007/s10198-012-0414-7Tat Chan, Chakravarthi Narasimhan, Ying Xie Treatment Effectiveness and Side Effects: A Model of Physician Learning, Management Science 59, no.66 (Jun 2013): 1309–1325.https://doi.org/10.1287/mnsc.1120.1640Victoria Serra-Sastre, Alistair McGuire Information and diffusion of new prescription drugs, Applied Economics 45, no.1515 (May 2013): 2049–2057.https://doi.org/10.1080/00036846.2011.648321Pierpaolo Cavallo, Sergio Pagano, Luna Carpinelli The Drug Prescription Process: A Network Medicine Approach, (Nov 2012): 537–562.https://doi.org/10.1007/978-1-4614-4998-0_32Mainak Mazumdar Introduction, (Jul 2012): 1–15.https://doi.org/10.1007/978-3-7908-2876-4_1Mainak Mazumdar Profitability of Indian Pharmaceutical Firms, (Jul 2012): 127–144.https://doi.org/10.1007/978-3-7908-2876-4_6S. A. Manickam, B. Sriram Modeling the Impact of Marketing Information on Consumer Buying Behavior in a Matured Marketing Environment: An Exploratory Study of the Middle East Consumers, Journal of Promotion Management 19, no.11 (Jan 2013): 1–16.https://doi.org/10.1080/10496491.2012.715127Mikael Linden Generic Substitution Effects on Firm Level Market Shares in the Finnish Beta Blocker Market 1997Q1-2007Q4, Modern Economy 04, no.1212 (Jan 2013): 852–863.https://doi.org/10.4236/me.2013.412092Andrew T. Ching, Masakazu Ishihara Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions, Management Science 58, no.77 (Jul 2012): 1374–1387.https://doi.org/10.1287/mnsc.1110.1499Despina A Karayanni, Christina C Georgi Segmenting generic medicines? market, using physicians? attitudes and generic companies? prescription span as grouping criteria, Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing 12, no.22 (Mar 2012): 104–122.https://doi.org/10.1177/1745790412443144Rena M. Conti, Meredith B. Rosenthal, Blase N. Polite, Peter B. Bach, Ya-Chen Tina Shih Infused Chemotherapy Use in the Elderly After Patent Expiration, Journal of Oncology Practice 8, no.3S3S (May 2012): e18s–e23s.https://doi.org/10.1200/JOP.2012.000541Ida Ferrara, Paul Missios Pricing of drugs with heterogeneous health insurance coverage, Journal of Health Economics 31, no.22 (Mar 2012): 440–456.https://doi.org/10.1016/j.jhealeco.2012.02.004Ahmed Driouchi, Nada Zouag Pharmaceutical Patents and Prices of Generics in Morocco and Neighboring Economies, The Journal of World Intellectual Property 15, no.22 (Mar 2012): 103–132.https://doi.org/10.1111/j.1747-1796.2012.00435.xAnat Lechner, Jeffrey S. Simonoff, Leslie Harrington Color-emotion associations in the pharmaceutical industry: Understanding Universal and local themes, Color Research & Application 37, no.11 (Aug 2011): 59–71.https://doi.org/10.1002/col.20643Jie Chen, John A. Rizzo Pricing dynamics and product quality: the case of antidepressant drugs, Empirical Economics 42, no.11 (Dec 2010): 279–300.https://doi.org/10.1007/s00181-010-0426-zAlon Eizenberg, Alberto Salvo Demand in the Wake of an Emerging Middle Class and Low-End Entry, SSRN Electronic Journal (Jan 2012).https://doi.org/10.2139/ssrn.1984594Tat Y. Chan, Chakravarthi Narasimhan, Ying Xie Treatment Effectiveness and Side Effects: A Model of Physician Learning, SSRN Electronic Journal (Jan 2012).https://doi.org/10.2139/ssrn.2134084Erin Cavusgil, Roger Calantone Are Pharmaceutical Marketing Decisions Calibrated to Communications Effects?, Health Marketing Quarterly 28, no.44 (Oct 2011): 317–336.https://doi.org/10.1080/07359683.2011.623105Maria Cristina Odasso, Elisa Ughetto Patent-backed securities in pharmaceuticals: what determines success or failure?, R&D Management 41, no.33 (May 2011): 219–239.https://doi.org/10.1111/j.1467-9310.2011.00646.xShamindra Nath Sanyal, Saroj Kumar Datta The effect of country of origin on brand equity: an empirical study on generic drugs, Journal of Product & Brand Management 20, no.22 (Apr 2011): 130–140.https://doi.org/10.1108/10610421111121125David Granlund, Niklas Rudholm Consumer Information and Pharmaceutical Prices: Theory and Evidence*, Oxford Bulletin of Economics and Statistics 73, no.22 (Nov 2010): 230–254.https://doi.org/10.1111/j.1468-0084.2010.00614.xJennifer L. Rice The influence of managed care on generic prescribing rates: an analysis of HMO physicians, Applied Economics 43, no.77 (Mar 2011): 787–796.https://doi.org/10.1080/00036840802600061Glenn Ellison, Sara Fisher Ellison Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration, American Economic Journal: Microeconomics 3, no.11 (Feb 2011): 1–36.https://doi.org/10.1257/mic.3.1.1Geoffrey K. Spurling, Peter R. Mansfield, Brett D. Montgomery, Joel Lexchin, Jenny Doust, Noordin Othman, Agnes I. Vitry, David Henry Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review, PLoS Medicine 7, no.1010 (Oct 2010): e1000352.https://doi.org/10.1371/journal.pmed.1000352Peter S. H. Leeflang, Jaap E. Wieringa Modeling the effects of pharmaceutical marketing, Marketing Letters 21, no.22 (Oct 2009): 121–133.https://doi.org/10.1007/s11002-009-9092-3W. DAVID BRADFORD, ANDREW N. KLEIT, PAUL J. NIETERT, STEVEN ORNSTEIN THE EFFECT OF DIRECT TO CONSUMER TELEVISION ADVERTISING ON THE TIMING OF TREATMENT, Economic Inquiry 48, no.22 (Apr 2010): 306–322.https://doi.org/10.1111/j.1465-7295.2009.00215.xD. Bardey, A. Bommier, B. Jullien Retail price regulation and innovation: Reference pricing in the pharmaceutical industry, Journal of Health Economics 29, no.22 (Mar 2010): 303–316.https://doi.org/10.1016/j.jhealeco.2009.11.015Ernst C. Osinga, Peter S.H. Leeflang, Jaap E. Wieringa Early Marketing Matters: A Time-Varying Parameter Approach to Persistence Modeling, Journal of Marketing Research 47, no.11 (Feb 2010): 173–185.https://doi.org/10.1509/jmkr.47.1.173Andrew Ching, Masakazu Ishihara Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions, SSRN Electronic Journal (Jan 2010).https://doi.org/10.2139/ssrn.1377255Jeremy Petranka A Threshold Interpretation of the Ratio-Form Contest Success Function, SSRN Electronic Journal (Jan 2010).https://doi.org/10.2139/ssrn.1639029Feng Gu, John Q. Li The Value-Relevance of Advertising: Evidence from Pharmaceutical Industry, Journal of Accounting, Auditing & Finance 25, no.11 (Jan 2010): 85–120.https://doi.org/10.1177/0148558X1002500104ALBERTO SALVO CUT-THROAT FRINGE COMPETITION IN AN EMERGING COUNTRY MARKET: TAX EVASION OR THE ABSENCE OF MARKET POWER?, The Journal of Industrial Economics 57, no.44 (Dec 2009): 677–711.https://doi.org/10.1111/j.1467-6451.2009.00400.x KIMTAEGI, Keun-Yeob Oh The Effects of KOR-US FTA on the Patents of Korean Pharmaceutical Industry, KUKJE KYUNGJE YONGU 15, no.33 (Dec 2009): 197–223.https://doi.org/10.17298/kky.2009.15.3.007Kurt R. Brekke, Odd Rune Straume Pharmaceutical Patents: Incentives for Research and Development or Marketing?, Southern Economic Journal 76, no.22 (Oct 2009): 351–374.https://doi.org/10.4284/sej.2009.76.2.351Sridhar Narayanan, Puneet Manchanda Heterogeneous Learning and the Targeting of Marketing Communication for New Products, Marketing Science 28, no.33 (May 2009): 424–441.https://doi.org/10.1287/mksc.1080.0410Wilfred Amaldoss, Chuan He Direct-to-Consumer Advertising of Prescription Drugs: A Strategic Analysis, Marketing Science 28, no.33 (May 2009): 472–487.https://doi.org/10.1287/mksc.1080.0411Elizabeth C Kwo, Priya Kamat, Michael A Steinman Physician Use of Brand Versus Generic Drug Names in 1993–1994 and 2003-2004, Annals of Pharmacotherapy 43, no.33 (Mar 2009): 459–468.https://doi.org/10.1345/aph.1L502Sara T.M. Kremer, Tammo H.A. Bijmolt, Peter S.H. Leeflang, Jaap E. Wieringa Generalizations on the effectiveness of pharmaceutical promotional expenditures, International Journal of Research in Marketing 25, no.44 (Dec 2008): 234–246.https://doi.org/10.1016/j.ijresmar.2008.08.001Jorge Gonzalez, Catarina Sismeiro, Shantanu Dutta, Philip Stern Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules, International Journal of Research in Marketing 25, no.44 (Dec 2008): 247–260.https://doi.org/10.1016/j.ijresmar.2008.08.002Julie M. Donohue, Michael A. Fischer, Haiden A. Huskamp, Joel S. Weissman Potential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription Drugs, Health Services Research 43, no.5p15p1 (May 2008): 1557–1575.https://doi.org/10.1111/j.1475-6773.2008.00858.xPAUL H. JENSEN, ELIZABETH WEBSTER LABELLING CHARACTERISTICS AND DEMAND FOR RETAIL GROCERY PRODUCTS IN AUSTRALIA, Australian Economic Papers 47, no.22 (Jun 2008): 129–140.https://doi.org/10.1111/j.1467-8454.2008.00336.xG Caleb Alexander, James Zhang, Anirban Basu Characteristics of Patients Receiving Pharmaceutical Samples and Association Between Sample Receipt and Out-of-Pocket Prescription Costs, Medical Care 46, no.44 (Apr 2008): 394–402.https://doi.org/10.1097/MLR.0b013e3181618ee0Alberto Salvo Cut-Throat Fringe Competition in an Emerging Country Market: Tax Evasion or the Absence of Market Power?, SSRN Electronic Journal (Jan 2008).https://doi.org/10.2139/ssrn.921143Yu Yu, Sachin Gupta Pioneering Advantage in Generic Drug Competition, SSRN Electronic Journal (Jan 2008).https://doi.org/10.2139/ssrn.925346Jorge Gonzalez, Catarina Sismeiro, Shantanu Dutta, Philip Stern Can Branded Drugs Benefit from Generic Entry? Switching to Non-Bioequivalent Molecules and the Role of Physician Response to Detailing and Prices, SSRN Electronic Journal (Jan 2008).https://doi.org/10.2139/ssrn.996552Winghan Jacqueline Kwong, Edward C. Norton The Effect of Advertising on Pharmaceutical Innovation, Review of Industrial Organization 31, no.33 (Oct 2007): 221–236.https://doi.org/10.1007/s11151-007-9146-8ALLEN N. BERGER, ASTRID A. DICK Entry into Banking Markets and the Early-Mover Advantage, Journal of Money, Credit and Banking 39, no.44 (Jun 2007): 775–807.https://doi.org/10.1111/j.1538-4616.2007.00046.xMichael A. Steinman, Mary-Margaret Chren, C. Seth Landefeld What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice, Journal of General Internal Medicine 22, no.55 (Jan 2007): 645–648.https://doi.org/10.1007/s11606-006-0074-3Ingrid Königbauer Advertising and generic market entry, Journal of Health Economics 26, no.22 (Mar 2007): 286–305.https://doi.org/10.1016/j.jhealeco.2006.08.008Joan-Ramon Borrell Pricing and patents of HIV/AIDS drugs in developing countries, Applied Economics 39, no.44 (Mar 2007): 505–518.https://doi.org/10.1080/00036840500438954Kyle Bagwell Chapter 28 The Economic Analysis of Advertising, (Jan 2007): 1701–1844.https://doi.org/10.1016/S1573-448X(06)03028-7Sridhar Narayanan, Puneet Manchanda Heterogeneous Learning and the Targeting of Marketing Communication for New Products, SSRN Electronic Journal (Jan 2007).https://doi.org/10.2139/ssrn.935339JULIE DONOHUE A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection, The Milbank Quarterly 84, no.44 (Dec 2006): 659–699.https://doi.org/10.1111/j.1468-0009.2006.00464.xJames O'Donnell Liability, Litigation, and Lessons in New Drug Development, (Dec 2009): 489–520.https://doi.org/10.1201/9781420004236.ch28David A. Soberman, Philip M. Parker The economics of quality-equivalent store brands, International Journal of Research in Marketing 23, no.22 (Jun 2006): 125–139.https://doi.org/10.1016/j.ijresmar.2005.09.008Frank Windmeijer, Eric de Laat, Rudy Douven, Esther Mot Pharmaceutical promotion and GP prescription behaviour, Health Economics 15, no.11 (Jan 2005): 5–18.https://doi.org/10.1002/hec.1007Kurt R. Brekke, Michael Kuhn Direct to consumer advertising in pharmaceutical markets, Journal of Health Economics 25, no.11 (Jan 2006): 102–130.https://doi.org/10.1016/j.jhealeco.2005.06.003Paul H. Jensen, Elizabeth M. Webster Market Power, Brand Characteristics and Demand for Retail Grocery Products, SSRN Electronic Journal (Jan 2006).https://doi.org/10.2139/ssrn.886462Toshiaki Iizuka, Ginger Zhe Jin The Effect of Prescription Drug Advertising on Doctor Visits, Journal of Economics <html_ent glyph="@amp;" ascii="&"/> Management Strategy 14, no.33 (Sep 2005): 701–727.https://doi.org/10.1111/j.1530-9134.2005.00079.xSridhar Narayanan, Puneet Manchanda, Pradeep K. Chintagunta Temporal Differences in the Role of Marketing Communication in New Product Categories, Journal of Marketing Research 42, no.33 (Oct 2018): 278–290.https://doi.org/10.1509/jmkr.2005.42.3.278Katia Campo, Odette De Staebel, Els Gijsbrechts, Walter van Waterschoot Physicians' Decision Process for Drug Prescription and the Impact of Pharmaceutical Marketing Mix Instruments, Health Marketing Quarterly 22, no.44 (Sep 2008): 73–107.https://doi.org/10.1300/J026v22n04_05Pradeep K. Chintagunta, Ramarao Desiraju Strategic Pricing and Detailing Behavior in International Markets, Marketing Science 24, no.11 (Feb 2005): 67–80.https://doi.org/10.1287/mksc.1030.0029Toshiaki Iizuka, Ginger Zhe Jin Direct to Consumer Advertising and Prescription Choice, SSRN Electronic Journal (Jan 2005).https://doi.org/10.2139/ssrn.700921David Bradford, Andrew N. Kleit, Paul Nietert, Steven Ornstein The Effect of Direct to Consumer Television Advertising on the Timing of Treatment, SSRN Electronic Journal (Jan 2005).https://doi.org/10.2139/ssrn.800564Julie M. Donohue, Ernst R. Berndt Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants, Journal of Public Policy & Marketing 23, no.22 (Oct 2018): 115–127.https://doi.org/10.1509/jppm.23.2.115.51395Gideon D. Markman, Maritza I. Espina, Phillip H. Phan Patents as Surrogates for Inimitable and Non-Substitutable Resources, Journal of Management 30, no.44 (Aug 2004): 529–544.https://doi.org/10.1016/j.jm.2003.09.005Frank Windmeijer, Eric de Laat, Rudy Douven, Esther Mot Pharmaceutical Promotion and GP Prescription Behaviour, SSRN Electronic Journal (Jan 2004).https://doi.org/10.2139/ssrn.536563Jun Ma, Randall S. Stafford, Iain M. Cockburn, Stan N. Finkelstein A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998, Clinical Therapeutics 25, no.55 (May 2003): 1503–1517.https://doi.org/10.1016/S0149-2918(03)80136-4Ronald J Vogel, Sulabha Ramachandran, Woodie M Zachry A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals, Clinical Therapeutics 25, no.11 (Jan 2003): 309–329.https://doi.org/10.1016/S0149-2918(03)90043-9Laura Ferrari Bravo, Luigi Luini The End of the Sole Mover Advantage: An Experiment, SSRN Electronic Journal (Jan 2003).https://doi.org/10.2139/ssrn.467350Luis E López, Edward B Roberts First-mover advantages in regimes of weak appropriability: the case of financial services innovations, Journal of Business Research 55, no.1212 (Dec 2002): 997–1005.https://doi.org/10.1016/S0148-2963(01)00200-4Pierre Azoulay Do Pharmaceutical Sales Respond to Scientific Evidence?, Journal of Economics <html_ent glyph="@amp;" ascii="&"/> Management Strategy 11, no.44 (Dec 2002): 551–594.https://doi.org/10.1111/j.1430-9134.2002.00551.x Davina C. Ling , Ernst R. Berndt , and Margaret K. Kyle Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales Ling/Berndt/Kyle, The Journal of Law and Economics 45, no.S2S2 (Jul 2015): 691–723.https://doi.org/10.1086/368004David A. Mott, Richard R. Cline Exploring Generic Drug Use Behavior, Medical Care 40, no.88 (Aug 2002): 662–674.https://doi.org/10.1097/00005650-200208000-00006Ya-Chen Tina Shih, Manishi Prasad, Bryan R. Luce The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: A microeconomic analysis, Clinical Therapeutics 24, no.44 (Apr 2002): 701–716.https://doi.org/10.1016/S0149-2918(02)85145-1Eduardo P.S. Fiuza, Marcos de Barros Lisboa Credence Goods and Market Power: An Econometric Study on the Brazilian Pharmaceutical Industry, SSRN Electronic Journal (Jan 2002).https://doi.org/10.2139/ssrn.297903Marta Wosinska Just What the Patient Ordered? Direct-to-Consumer Advertising and the Demand for Pharmaceutical Products, SSRN Electronic Journal (Jan 2002).https://doi.org/10.2139/ssrn.347005Charles King Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs, SSRN Electronic Journal (Jan 2002).https://doi.org/10.2139/ssrn.891128Füsun F. Gönül, Franklin Carter, Elina Petrova, Kannan Srinivasan Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior, Journal of Marketing 65, no.33 (Oct 2018): 79–90.https://doi.org/10.1509/jmkg.65.3.79.18329 Christophe Van den Bulte and Gary L. Lilien Medical Innovation Revisited: Social Contagion versus Marketing Effort Van de Bulte and Lilien, American Journal of Sociology 106, no.55 (Jul 2015): 1409–1435.https://doi.org/10.1086/320819C. Freund Different Paths to Free Trade: The Gains from Regionalism, The Quarterly Journal of Economics 115, no.44 (Nov 2000): 1317–1341.https://doi.org/10.1162/003355300555088Fiona M. Scott Morton Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry, International Journal of Industrial Organization 18, no.77 (Oct 2000): 1085–1104.https://doi.org/10.1016/S0167-7187(98)00057-5H. D. Vinod, P. M. Rao R&D and Promotion in Pharmaceuticals: A Conceptual Framework and Empirical Exploration, Journal of Marketing Theory and Practice 8, no.44 (Dec 2015): 10–20.https://doi.org/10.1080/10696679.2000.11501876Douglas Lundin Moral hazard in physician prescription behavior, Journal of Health Economics 19, no.55 (Sep 2000): 639–662.https://doi.org/10.1016/S0167-6296(00)00033-3John Hudson Generic take-up in the pharmaceutical market following patent expiry, International Review of Law and Economics 20, no.22 (Jun 2000): 205–221.https://doi.org/10.1016/S0144-8188(00)00030-2 By John A. Rizzo Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs Rizzo, The Journal of Law and Economics 42, no.11 (Jul 2015): 89–116.https://doi.org/10.1086/467419Karel Cool, Lars-Hendrik Röller, Benoit Leleux The relative impact of actual and potential rivalry on firm profitability in the pharmaceutical industry, Strategic Management Journal 20, no.11 (Jan 1999): 1–14.https://doi.org/10.1002/(SICI)1097-0266(199901)20:1&lt;1::AID-SMJ995&gt;3.0.CO;2-XAndrew N. Kleit Using Advertising to Generate Information and Signals for Product Quality: Lessons for Biotechnology Markets in Canada from Pharmaceutical Markets in the United States, (Jan 1998): 257–275.https://doi.org/10.1007/978-1-4615-5311-3_9Dennis C. Mueller First-mover advantages and path dependence, International Journal of Industrial Organization 15, no.66 (Oct 1997): 827–850.https://doi.org/10.1016/S0167-7187(97)00013-1Thomas A. Abbott Price regulation in the pharmaceutical industry: Prescription or placebo?, Journal of Health Economics 14, no.55 (Dec 1995): 551–565.https://doi.org/10.1016/0167-6296(95)00022-4Thomas A. Abbott Regulating Pharmaceutical Prices, (Jan 1995): 105–141.https://doi.org/10.1007/978-1-4615-2219-5_7William T. Robinson, Gurumurthy Kalyanaram, Glen L. Urban First-mover advantages from pioneering new markets: A survey of empirical evidence, Review of Industrial Organization 9, no.11 (Feb 1994): 1–23.https://doi.org/10.1007/BF01024216Thomas K. Hazlet, Sean D. Sullivan, Klaus M. Leisinger, Laura Gardner, William E. Fassett, Jon R. May Professional Organizations and Healthcare Industry Support: Ethical Conflict?, Cambridge Quarterly of Healthcare Ethics 3, no.22 (Jul 2009): 236–256.https://doi.org/10.1017/S0963180100004977Stefan Höög Over-the-Counter Drug Advertising: Argumentation or Persuasion?, Journal of Pharmaceutical Marketing & Management 9, no.22 (Dec 2011): 69–91.https://doi.org/10.3109/J058v09n02_04Karel Cool, Ingemar Dierickx Rivalry, strategic groups and firm profitability, Strategic Management Journal 14, no.11 (Nov 2006): 47–59.https://doi.org/10.1002/smj.4250140106 Henry G. Grabowski , and John M. Vernon Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act, The Journal of Law and Economics 35, no.22 (Oct 2015): 331–350.https://doi.org/10.1086/467257John Cawley, John A. Rizzo Spillover effects of prescription drug withdrawals, (): 119–143.https://doi.org/10.1016/S0731-2199(08)19006-9